CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.643
EU - Europa 3.504
AS - Asia 1.184
SA - Sud America 53
AF - Africa 52
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.471
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.591
CN - Cina 739
IT - Italia 733
DK - Danimarca 579
IE - Irlanda 471
SE - Svezia 420
FR - Francia 258
AT - Austria 245
DE - Germania 156
UA - Ucraina 156
FI - Finlandia 147
GB - Regno Unito 114
VN - Vietnam 99
IN - India 92
KR - Corea 68
NL - Olanda 48
CA - Canada 39
JP - Giappone 37
BE - Belgio 34
PL - Polonia 32
ES - Italia 28
HK - Hong Kong 28
AU - Australia 26
SG - Singapore 23
BR - Brasile 22
GR - Grecia 18
TH - Thailandia 18
EG - Egitto 16
RO - Romania 15
CL - Cile 13
RU - Federazione Russa 13
PK - Pakistan 11
ID - Indonesia 10
MX - Messico 10
TR - Turchia 10
TW - Taiwan 10
ZA - Sudafrica 10
NG - Nigeria 9
UZ - Uzbekistan 9
CO - Colombia 8
EU - Europa 8
CH - Svizzera 7
CZ - Repubblica Ceca 6
SN - Senegal 6
IL - Israele 5
PT - Portogallo 5
MY - Malesia 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
EC - Ecuador 3
RS - Serbia 3
TN - Tunisia 3
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
KZ - Kazakistan 2
LK - Sri Lanka 2
ME - Montenegro 2
MO - Macao, regione amministrativa speciale della Cina 2
MW - Malawi 2
NO - Norvegia 2
PE - Perù 2
QA - Qatar 2
BD - Bangladesh 1
BF - Burkina Faso 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 11.471
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.314
Chandler 984
Dublin 470
Beijing 435
Fairfield 341
Torino 312
Houston 289
Woodbridge 251
Nyköping 221
Ashburn 207
Vienna 201
Dearborn 195
Villeurbanne 190
Wilmington 184
Medford 141
Princeton 133
Cambridge 116
Seattle 112
Fremont 102
Redwood City 96
Jacksonville 94
Turin 65
New York 53
Boardman 46
Dong Ket 43
Boston 38
Pisa 37
Milan 36
Nanjing 34
Washington 32
Shanghai 31
Hangzhou 29
Brussels 27
San Diego 23
Warsaw 23
Guangzhou 21
Toronto 21
Hebei 19
Hefei 19
Norwalk 18
Chengdu 17
Verona 16
Seoul 13
Tokyo 12
Jinan 11
Mountain View 11
Cairo 10
Falls Church 10
Pune 10
Rome 10
Zhengzhou 10
Central District 9
Cinisello Balsamo 9
Genoa 9
Hyderabad 9
London 9
Los Angeles 9
Abuja 8
Edinburgh 8
Kunming 8
Mumbai 8
Nanchang 8
Silver Spring 8
Singapore 8
Chicago 7
Des Moines 7
Lappeenranta 7
Phoenix 7
Taipei 7
Barcelona 6
Columbus 6
Helsinki 6
Jakarta 6
Medellín 6
Shenzhen 6
Tianjin 6
Athens 5
Bologna 5
Cape Town 5
Chongqing 5
Esslingen am Neckar 5
Falkenstein 5
Guiyang 5
Islamabad 5
Las Condes 5
Munich 5
Ottawa 5
Wuhan 5
Aachen 4
Andover 4
Bakersfield 4
Bangkok 4
Bengaluru 4
Buffalo 4
Changsha 4
Copenhagen 4
Dallas 4
Düsseldorf 4
Hong Kong 4
Kharkiv 4
Totale 7.428
Salva come PNG Salva come JPEG
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 387
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 366
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 234
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 222
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 209
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 207
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 183
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 181
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 180
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 173
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 172
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 168
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 168
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 165
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 164
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 158
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 156
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 151
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 148
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 146
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 145
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 144
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 143
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 137
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 135
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 134
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 130
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 129
Pharmacogenetics of ribavirin-induced anemia in HCV patients 128
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 125
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 125
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 124
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 122
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 119
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 117
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 115
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 113
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 104
Cannabinoids concentration variability in cannabis olive oil galenic preparations 104
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 103
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 101
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 99
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 98
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 95
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 93
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 92
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 92
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 91
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 89
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 89
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 87
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 87
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 86
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 84
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 82
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 81
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 81
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 81
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 77
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 76
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 74
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 73
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 72
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 71
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 69
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 67
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 67
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 66
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 66
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 65
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 64
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 63
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 63
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 62
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 62
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 62
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 60
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 59
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 59
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 58
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 57
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 57
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence 57
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 55
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump 55
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 55
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 55
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 54
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 54
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 53
Antiretroviral concentrations in the presence and absence of valproic acid 53
Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection? 52
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 51
Precision medicine for HIV: where are we? 51
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 50
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir. 49
Data on the stability of darunavir/cobicistat suspension after tablet manipulation 49
Totale 10.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.697
article - articoli 0
book - libri 0
conference - conferenze 5.071
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019322 0 0 0 0 0 0 0 0 0 125 117 80
2019/20201.960 39 40 49 138 183 369 168 110 180 258 193 233
2020/20211.453 164 75 50 90 116 104 107 52 105 115 191 284
2021/20222.447 176 193 196 196 156 213 181 152 114 129 388 353
2022/20232.773 249 234 71 258 253 659 164 230 315 61 182 97
2023/2024827 154 194 78 54 64 152 28 51 13 39 0 0
Totale 12.120